EXPERT POINT OF VIEW: Deborah J.L. Wong, MD, PhD


Get Permission

Error loading Partial View script (file: ~/Views/MacroPartials/TAP Article Portrait Widget.cshtml)

DISCUSSANT FOR THIS abstract, Deborah J.L. Wong, MD, PhD, of the David Geffen School of Medicine at the University of California, highlighted the preclinical rationale, as well as in vitro and in vivo data, supporting the potential benefit of poly (ADP-ribose) polymerase (PARP) inhibitors in combination with immunotherapy.

“This study offers an interesting signal of activity, particularly in patients with BRCA mutations,” said Dr. Wong. “It’s interesting to note that among the patients with BRCA mutations, all of them experienced at least stable disease as their best response.”

Careful understanding of the mechanisms of toxicity will be key as the trial progresses, Dr. Wong concluded. ■

DISCLOSURE: Dr. Wong has served as a consultant or advisor to Bristol-Myers Squibb and has received research funding from ARMO BioSciences, AstraZeneca/MedImmune, BioMed Valley Discoveries, Kura, Merck Serono, and Merck Sharp & Dohme.


Related Articles

Combination PARP and PD-1 Inhibition Shows Antitumor Activity in Advanced Malignancies

IN A PHASE I trial of patients with advanced solid tumors, the combination of pamiparib (BGB-290), a selective poly (ADP-ribose) polymerase (PARP) inhibitor, and tislelizumab (BGB-A317), an agent targeting the programmed cell death protein 1 (PD-1) receptor, was well tolerated while demonstrating...

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.